By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exact Sciences today reported that it had cut its fourth-quarter net loss 14 percent, as it took in licensing fees that were more than three times greater than those received in Q4 2008.

The Madison, Wis.-based molecular diagnostics developer said that it brought in $1.2 million in licensing fees for the three-month period ended Dec. 31, compared to $338,000 for the fourth quarter of 2008. The company reported no product revenues for either period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.